{"id":"sok583a1","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the target, which leads to a specific therapeutic effect. This mechanism is still under investigation.","oneSentence":"SOK583A1 is a small molecule drug that targets the molecular target.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:17.041Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04864834","phase":"PHASE3","title":"Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Sandoz","startDate":"2021-05-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":485},{"nctId":"NCT05282004","phase":"PHASE3","title":"Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit","status":"COMPLETED","sponsor":"Sandoz","startDate":"2022-05-16","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":36},{"nctId":"NCT05161806","phase":"PHASE3","title":"Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe","status":"COMPLETED","sponsor":"Sandoz","startDate":"2022-03-11","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SOK583A1","genericName":"SOK583A1","companyName":"Sandoz","companyId":"sandoz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SOK583A1 is a small molecule drug that targets the molecular target. Used for Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}